インドの乳がん治療市場：タイプ別、治療タイプ別、エンドユーザー別、地域別、機会、予測、2019年～2033年

インドの乳がん治療の市場規模は、2026年～2033年の予測期間中に11.17％のCAGRで拡大し、2025年の5億578万米ドルから2033年には11億7,966万米ドルに成長すると予測されています。同市場の成長は、国内における乳がん患者の増加、乳がんと闘うための先進的な治療ソリューションを導入するための研究機関の努力の増加、市場の大手企業による新規の上市によって増強されています。IARC-WHOのGlobal Cancer Observatoryによると、2022年、インドでは女性の乳がんが原因で98,337人が死亡しています。

政府の取り組みが活発化し、ヘルスケアのインフラ整備が重視され、乳がんに対する意識が高まっているため、乳がん治療へのアクセスはインド全土で増加しています。医療技術の進歩や、標的療法、免疫療法、抗体薬物複合体などの革新的な治療法の導入により、インドで利用できる効果的な治療選択肢の幅が広がっています。さらに、がん専門医療センターの設立や診断施設の改善により、より良い疾病管理が保証され、市場の拡大にプラスの影響を与えています。一方、晩期診断、高額な治療費、腫瘍専門医の不足が市場成長の課題となっています。

当レポートでは、インドの乳がん治療市場について調査し、市場の概要とともに、タイプ別、治療タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税がインドの乳がん治療市場に与える影響

第4章 エグゼクティブサマリー

第5章 インドの乳がん治療市場の見通し、2019年～2033年

• 市場規模分析と予測
• 市場シェア分析と予測
  • タイプ別
    • 乳管内がん（DCIS）
    • 浸潤性乳管がん（IDC）
    • 上皮内小葉がん（LCIS）
    • 浸潤性小葉がん（ILC）
    • トリプルネガティブ乳がん
    • 炎症性乳がん（IBC）
    • 転移性乳がん
    • 妊娠中の乳がん
    • その他
  • 治療タイプ別
    • 手術
    • 放射線治療
    • 化学療法
    • ホルモン療法
    • 標的療法
    • 免疫療法
    • その他
  • エンドユーザー別
    • がん研究機関
    • 病院
    • 外来手術センター
    • その他
  • 地域別
    • 北部
    • 南部
    • 東部
    • 西部と中央部
  • 企業別市場シェア分析（上位5社およびその他- 金額ベース、2025年）
• 2025年の市場マップ分析

第6章 需要供給分析

第7章 バリューチェーン分析

第8章 ポーターのファイブフォース分析

第9章 PESTLE分析

第10章 価格分析

第11章 市場力学

• 市場の促進要因
• 市場の課題

第12章 市場動向と発展

第13章 規制枠組みとイノベーション

• 規制当局の承認
• 臨床試験

第14章 特許の情勢

第15章 ケーススタディ

第16章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要企業トップ10の情勢
  • Novartis Healthcare Private Limited
  • Pfizer India Inc.
  • Eisai Pharmaceuticals India Pvt. Ltd.
  • Merck & Co., Inc.
  • Kyowa Kirin Co., Ltd.
  • Eli Lilly and Company (India) Pvt. Ltd.
  • Bristol Myers Squibb India Pvt Ltd
  • AstraZeneca Pharma India Limited
  • Sanofi India Limited
  • Daiichi Sankyo Company, Limited

第17章 戦略的提言

第18章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. India Breast Cancer Treatment Market, By Value, In USD Million, FY2019-FY2033F
• Figure 2. India Breast Cancer Treatment Market Share (%), By Type, FY2019-FY2033F
• Figure 3. India Breast Cancer Treatment Market Share (%), By Treatment Type, FY2019-FY2033F
• Figure 4. India Breast Cancer Treatment Market Share (%), By End-user, FY2019-FY2033F
• Figure 5. India Breast Cancer Treatment Market Share (%), By Region, FY2019-FY2033F
• Figure 6. By Type Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 7. By Treatment Type Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 8. By End-user Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 9. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2025

India breast cancer treatment market is projected to witness a CAGR of 11.17% during the forecast period FY2026-FY2033, growing from USD 505.78 million in FY2025 to USD 1179.66 million in FY2033. The market's growth is augmented by the rising cases of breast cancer in the country, increasing efforts of research organizations to introduce advanced therapeutic solutions to combat breast cancer, and novel launches by leading players of the market. According to the Global Cancer Observatory, IARC-WHO, 2022, 98,337 deaths occurred due to breast cancer among females in 2022 in India.

The accessibility of breast cancer treatment is increasing across India due to the rising government initiatives, focus on improving healthcare infrastructure, and growing awareness about the condition. Advancements in medical technology and the introduction of innovative therapies, including targeted therapies, immunotherapies, and antibody-drug conjugates, are broadening the range of effective treatment options available in India. Additionally, the establishment of specialized cancer centers and improved diagnostic facilities are ensuring better disease management and positively influencing the market's expansion. Meanwhile, late-stage diagnosis in several cases, high costs of treatment, and lack of oncologists in the country pose challenges to the market's growth.

Increasing Efforts to Improve Breast Cancer Diagnosis Boosts Market Growth

Rising efforts to ensure early detection of breast cancer across the country are propelling the market's expansion as they are allowing the identification of cases at more treatable stages, augmenting the demand for treatment services. For instance, in November 2024, a team of oncologists under the Cancer Mukt Bharat campaign launched India's first 24x7 free Pink Cancer Helpline for promoting early detection of breast cancer. The helpline offers guidance via video and phone consultations, including preventive advice and self-examination instructions at no cost. Such initiatives promote awareness about breast cancer, reduce delays, and improve patient access to diagnostic technologies, in turn propelling the expansion of the market.

Increasing Research Efforts of Educational Organizations Support Market Expansion

Rising research efforts by educational organizations are fostering innovation, improving early detection of breast cancer, and enhancing patient outcomes. Institutions like the Cancer Research Institute at the Himalayan Institute of Medical Sciences has launched specialized clinics, including India's first Young Breast Cancer Clinic, to address the unique requirements of younger patients. Such efforts provide tailored care, promote targeted research, and set new benchmarks for breast cancer treatment and awareness.

Additionally, increasing research efforts are allowing institutes to receive approvals and patents, further encouraging different organizations to continue on with their research efforts. For instance, in February 2025, researchers from IIT Madras successfully developed and patented a next generation drug delivery system for treating breast cancer. The patented technology encapsulates anti-cancer drugs in the nanoparticles that directly target cancer cells, reducing side effects and minimizing damage to healthy tissues.

Development of New Breast Cancer Therapies is Driving the Market's Growth

The growing efforts of pharmaceutical companies and research organizations to boost the introduction of innovative breast cancer therapies in India is positively influencing the market's expansion. The availability of novel treatment solutions allows medical professionals to address the critical unmet requirements of the patient population and ensures that patients who previously had limited treatment options available have access to advanced therapies.

Research institutions across India are focusing on developing advanced therapies to improve drug delivery systems in order to combat the rising cases of breast cancer in the country. For instance, in January 2025, researchers from Institute Kolkata and IIT Guwahati developed an innovative injectable hydrogel for targeted breast cancer therapy. The hydrogel releases anti-cancer drugs in a controlled manner. The hydrogel reduces damage to healthy cells and minimizes systemic side effects by ensuring the delivery of chemotherapy drugs directly in the tumor sites.

Hospitals Holds Major Market Share

Hospital account for a significant share of the market as they have access to advanced therapeutic solutions and diagnostic technologies, provide multidisciplinary care, and a comprehensive infrastructure. Additionally, hospitals are better equipped to participate in clinical trials and invest in new technologies, enhancing treatment outcomes. Hospitals also act as key locations for screening programs and cancer awareness, improving the rate of diagnosis and thus treatment uptake. Moreover, a rising number of cancer hospitals are being constructed across the country to ensure that the patient population is provided with the required treatment solutions, thus bolstering the market's demand. For instance, in December 2024, the newly built Dr Sampat Kumar S. Shivangi Cancer Hospital was inaugurated in Karnataka. Such efforts are increasing the availability of advanced cancer care and improving diagnosis rates and treatment outcomes in underserved regions.

Impact of the U.S. Tariff on India Breast Cancer Treatment Market

Pharmaceutical exports have been exempted from the recent tariffs, however, the medical device industry, which is integral for early detection and treatment of cancer, is expected to face substantial challenges. Healthcare professionals might face challenges in procuring advanced equipment, hindering the diagnostic process, which is particularly crucial for ensuring effective treatment of breast cancer.

Additionally, the tariffs are going to impact Indian medical device manufacturers that export their products to the United States and result in decreased revenues, potentially limiting their resources for research and development activities, constraining the availability of novel diagnostic and therapeutic solutions.

Key Players Landscape and Outlook

The key players of the market are focusing on launching new drugs to aid the patient population in combating the disease and expanding their presence in the market. For instance, in January 2024, AstraZeneca Pharma India Limited launched Trastuzumab deruxtecan in India for treating adults with metastatic or unresectable HER2 positive breast cancer who have already received an anti-HER2 regimen. The introduction of this drug is seen as a major advancement, providing a transformative option for patients with aggressive breast cancer. Such launches address the critical unmet requirements of the patients by expanding the available treatment options.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariff on India Breast Cancer Treatment Market

4. Executive Summary

5. India Breast Cancer Treatment Market Outlook, FY2019-FY2033F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Type
    • 5.2.1.1. Ductal Carcinoma In Situ (DCIS)
    • 5.2.1.2. Invasive Ductal Carcinoma (IDC)
    • 5.2.1.3. Lobular Carcinoma In Situ (LCIS)
    • 5.2.1.4. Invasive Lobular Cancer (ILC)
    • 5.2.1.5. Triple Negative Breast Cancer
    • 5.2.1.6. Inflammatory Breast Cancer (IBC)
    • 5.2.1.7. Metastatic Breast Cancer
    • 5.2.1.8. Breast Cancer During Pregnancy
    • 5.2.1.9. Other Types
  • 5.2.2. By Treatment Type
    • 5.2.2.1. Surgery
    • 5.2.2.2. Radiation Therapy
    • 5.2.2.3. Chemotherapy
    • 5.2.2.4. Hormonal Therapy
      • 5.2.2.4.1. Selective Estrogen Receptor Modulators
      • 5.2.2.4.2. Aromatase Inhibitors
      • 5.2.2.4.3. Estrogen Receptor Downregulators
    • 5.2.2.5. Targeted Therapy
      • 5.2.2.5.1. Abemaciclib
      • 5.2.2.5.2. Adotrastuzumab Emtansine
      • 5.2.2.5.3. Everolimus
      • 5.2.2.5.4. Trastuzumab
      • 5.2.2.5.5. Ribociclib
      • 5.2.2.5.6. Palbocicib
      • 5.2.2.5.7. Pertuzumab
      • 5.2.2.5.8. Olaparib
      • 5.2.2.5.9. Others
    • 5.2.2.6. Immunotherapy
    • 5.2.2.7. Others
  • 5.2.3. By End-user
    • 5.2.3.1. Cancer Research Institutes
    • 5.2.3.2. Hospitals
    • 5.2.3.3. Ambulatory Surgical Centers
    • 5.2.3.4. Others
  • 5.2.4. By Region
    • 5.2.4.1. North
    • 5.2.4.2. South
    • 5.2.4.3. East
    • 5.2.4.4. West & Central
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
• 5.3. Market Map Analysis, FY2025
  • 5.3.1. By Type
  • 5.3.2. By Treatment Type
  • 5.3.3. By End-user
  • 5.3.4. By Region

6. Demand Supply Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Regulatory Approvals
• 13.2. Clinical Trials

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. Novartis Healthcare Private Limited
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 16.3.2. Pfizer India Inc.
  • 16.3.3. Eisai Pharmaceuticals India Pvt. Ltd.
  • 16.3.4. Merck & Co., Inc.
  • 16.3.5. Kyowa Kirin Co., Ltd.
  • 16.3.6. Eli Lilly and Company (India) Pvt. Ltd.
  • 16.3.7. Bristol Myers Squibb India Pvt Ltd
  • 16.3.8. AstraZeneca Pharma India Limited
  • 16.3.9. Sanofi India Limited
  • 16.3.10. Daiichi Sankyo Company, Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer